Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LCTX Stock Forecast 2025-2026
$0.86
Current Price
$196.02M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to LCTX Price Targets
+946.5%
To High Target of $9.00
+248.8%
To Median Target of $3.00
+74.4%
To Low Target of $1.50
LCTX Price Momentum
+22.9%
1 Week Change
+72.0%
1 Month Change
-3.4%
1 Year Change
+72.0%
Year-to-Date Change
-25.2%
From 52W High of $1.15
+132.4%
From 52W Low of $0.37
📊 TOP ANALYST CALLS
Did LCTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lineage is one of their latest high-conviction picks.
Latest LCTX Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, LCTX has a bullish consensus with a median price target of $3.00 (ranging from $1.50 to $9.00). Currently trading at $0.86, the median forecast implies a 248.8% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 946.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LCTX Analyst Ratings
6
Buy
1
Hold
0
Sell
LCTX Price Target Range
Low
$1.50
Average
$3.00
High
$9.00
Current: $0.86
Latest LCTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LCTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $3.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $9.00 |
| Mar 11, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $2.00 |
| Feb 11, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $9.00 |
| Feb 11, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $2.00 |
| Jan 31, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $9.00 |
| Jan 10, 2025 | Maxim Group | Michael Okunewitch | Buy | Maintains | $3.00 |
| Jan 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $2.00 |
| Dec 4, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $9.00 |
| Nov 20, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $2.00 |
| Nov 18, 2024 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $3.00 |
| Aug 20, 2024 | Craig-Hallum | Albert Lowe | Buy | Initiates | $4.00 |
| May 6, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| Mar 8, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| Feb 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| Feb 5, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $6.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| Jul 25, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $0.00 | |
| Jul 24, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 12, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
Lineage Cell Therapeutics Inc. (LCTX) Competitors
The following stocks are similar to Lineage based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lineage Cell Therapeutics Inc. (LCTX) Financial Data
Lineage Cell Therapeutics Inc. has a market capitalization of $196.02M with a P/E ratio of -10.2x. The company generates $9.56M in trailing twelve-month revenue with a -169.6% profit margin.
Revenue growth is +4.0% quarter-over-quarter, while maintaining an operating margin of -433.1% and return on equity of -21.8%.
Valuation Metrics
Market Cap
$196.02M
Enterprise Value
$148.99M
P/E Ratio
-10.2x
PEG Ratio
-5.7x
Price/Sales
20.5x
Growth & Margins
Revenue Growth (YoY)
+4.0%
Gross Margin
+97.6%
Operating Margin
-433.1%
Net Margin
-169.6%
EPS Growth
+4.0%
Financial Health
Cash/Price Ratio
+24.4%
Current Ratio
3.8x
Debt/Equity
2.9x
ROE
-21.8%
ROA
-12.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lineage Cell Therapeutics Inc. (LCTX) Business Model
About Lineage Cell Therapeutics Inc.
What They Do
Develops novel cell therapies for degenerative diseases.
Business Model
Lineage Cell Therapeutics generates revenue through the development and commercialization of allogeneic cell therapies that provide treatment alternatives for conditions like spinal cord injuries and cancer. The company leverages its proprietary platform to create innovative therapies aimed at addressing unmet medical needs.
Additional Information
With a focus on regenerative medicine, Lineage Cell Therapeutics is positioned as a key player in biotechnology, potentially transforming standard care practices. Its commitment to technological advancement makes it a significant entity in sectors like healthcare and pharmaceuticals.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
70
CEO
Mr. Brian M. Culley M.A., M.B.A.
Country
United States
IPO Year
1992
Website
www.lineagecell.comLineage Cell Therapeutics Inc. (LCTX) Latest News & Analysis
Latest News
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
13 days ago
Quick Summary
Lineage Cell Therapeutics (NYSE: LCTX) will participate in the fully virtual 3rd Annual Spinal Cord Injury Investor Symposium starting June 27, 2025, featuring additional presenters.
Why It Matters
The announcement of additional presenters for the 3rd SCIIS highlights growing interest in innovative therapies, potentially influencing investor sentiment and stock performance for Lineage Cell Therapeutics.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) will hold its Q1 2025 earnings conference call on May 13, 2025, at 4:30 PM ET, featuring key executives and analysts from various firms.
Why It Matters
The earnings conference call provides insights into Lineage Cell Therapeutics’ financial performance and strategic direction, which can influence stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
1 month ago
Quick Summary
Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 2025 financial results and will hold a conference call today at 4:30 PM ET to discuss its progress and updates on its allogeneic cell therapies.
Why It Matters
Lineage Cell Therapeutics' positive financial results and confidence in its OpRegen therapy could indicate growth potential, impacting stock performance and investment strategies in biotech.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Lineage Cell (LCTX) reported a quarterly loss of $0.02 per share, matching estimates and improving from a loss of $0.04 per share a year prior.
Why It Matters
Lineage Cell's smaller quarterly loss indicates improved financial performance year-over-year, aligning with expectations, which may enhance investor confidence and stabilize stock prices.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Lineage Cell Therapeutics (NYSE: LCTX) will present 36-month results from a Phase 1/2a study of RG6501 (OpRegen) for geographic atrophy due to age-related macular degeneration.
Why It Matters
The announcement of 36-month results from a Phase 1/2a study on RG6501 could influence LCTX's stock performance, reflecting investor confidence in the company's potential for breakthroughs in treating AMD.
Source: Business Wire
Market Sentiment:
Neutral
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
1 month ago
Quick Summary
Lineage Cell Therapeutics (NYSE: LCTX) CEO Brian M. Culley will present at the H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at 2:30 PM ET.
Why It Matters
CEO presentations at investor conferences can signal company progress and attract investor interest, potentially impacting stock prices and market sentiment for Lineage Cell Therapeutics.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About LCTX Stock
What is Lineage Cell Therapeutics Inc.'s (LCTX) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Lineage Cell Therapeutics Inc. (LCTX) has a median price target of $3.00. The highest price target is $9.00 and the lowest is $1.50.
Is LCTX stock a good investment in 2025?
According to current analyst ratings, LCTX has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.86. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LCTX stock?
Wall Street analysts predict LCTX stock could reach $3.00 in the next 12 months. This represents a 248.8% increase from the current price of $0.86. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lineage Cell Therapeutics Inc.'s business model?
Lineage Cell Therapeutics generates revenue through the development and commercialization of allogeneic cell therapies that provide treatment alternatives for conditions like spinal cord injuries and cancer. The company leverages its proprietary platform to create innovative therapies aimed at addressing unmet medical needs.
What is the highest forecasted price for LCTX Lineage Cell Therapeutics Inc.?
The highest price target for LCTX is $9.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 946.5% increase from the current price of $0.86.
What is the lowest forecasted price for LCTX Lineage Cell Therapeutics Inc.?
The lowest price target for LCTX is $1.50 from at , which represents a 74.4% increase from the current price of $0.86.
What is the overall LCTX consensus from analysts for Lineage Cell Therapeutics Inc.?
The overall analyst consensus for LCTX is bullish. Out of 8 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are LCTX stock price projections?
Stock price projections, including those for Lineage Cell Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 2:37 AM UTC